Mistral Ventures Inc. (OTC:MILV) closed the day up 44% at $0.0650 with over 207 million shares traded. Earlier today, MILV released news that its subsidiary Nature’s Bioceuticals reached an agreement with an inventor of a cold and flu medicine.
Robert deZanger, CEO of Natures Bioceuticals had this about the agreement, “Although the Cold and Flu market is flooded with a number of established brands, we are confident that we can capture a significant portion of the market with an all natural product that really works. The company has the potential to capture 3% of the US market within a 3 year period, which would potentially generate over $100,000,000 in revenues for the company. Our formula contains over twenty different herbs that are all ‘active ingredients.’ The formula provides relief from the cold and flu symptoms, but more importantly, it boosts the body’s immune response to combat the cause of the virus. When taken at the onset of symptoms the formula has shown the ability to reduce the severity and duration of a cold or flu. It has also in many cases arrested the virus before symptoms are able to come to fruition. The inventor has for many years been conducting research to find a ‘cure’ for the common cold. This formula was invented as a result of that ongoing research. Upon closing of the purchase we intend to hire an independent testing group to do a clinical trial(s) to formally document the results we have achieved and publish a report for the medical community.”
Mistral Ventures Inc. (OTC:MILV) is also being promoted by multiple newsletters. That’s why it is trading so much volume today. Will it continue to go up tomorrow or will traders want their profits? Stay tuned.
After you get your fill of penny stocks be sure to check out active-investor.com. Recently launched, Active Investor is the new go to hub for all things big board related. Covering the latest in the stock market today, Active Investor is quickly becoming the premiere destination for coverage of the NYSE, NASDAQ, and related big board exchanges.
Disclaimer: This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in this stock at the time of this posting. Do not use the above information as investment advice. It is for entertainment purposes only. Penny Stock Classroom is not liable for any losses you may incur.
